A human papilloma virus testing algorithm comprising a combination of the l1 broad-spectrum spf10 pcr assay and a novel e6 high-risk multiplex type-specific genotyping PCR assay

Journal of Clinical Microbiology

Volumn 51, Issue 4, 2013, Pages 1171-1178

  Van Alewijk, Dirk ^a   Kleter, Bernhard ^a   Vent, Maarten ^a   Delroisse, Jean Marc ^b   De Koning, Maurits ^a   Van Doorn, Leen Jan ^a   Quint, Wim ^a   Colau, Brigitte ^b  

^a DDL DIAGNOSTIC LABORATORY   (Netherlands)

^b GSK   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA ENZYME IMMUNOASSAY SYSTEM; FALSE NEGATIVE RESULT; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN TISSUE; INTERMETHOD COMPARISON; LIMIT OF DETECTION; NONHUMAN; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS DETECTION; VIRUS IDENTIFICATION;

ALGORITHMS; BIOPSY; CERVIX UTERI; CLINICAL LABORATORY TECHNIQUES; FEMALE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

EID: 84875822697     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02831-12     Document Type: Article

References (27)

1. Baay MF, Quint WG, Koudstaal J, Hollema H, Duk JM, Burger MP, Stolz E, Herbrink P. 1996. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J. Clin. Microbiol. 34: 745-747.
2. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:70-79.
3. Chan SY, Delius H, Halpern AL, Bernard HU. 1995. Analysis of genomic sequences of 95 papillomavirus types: Uniting typing, phylogeny, and taxonomy. J. Virol. 69:3074-3083.
4. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. 1995. The use of general primers GP5 and GP6 elongated at their 3= ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol. 76:1057-1062.
5. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menendez C, Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF, Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C, Ordi J, Andujar M, Castellsague X, Sanchez GI, Nowakowski AM, Bornstein J, Munoz N, Bosch FX. 2010. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 11:1048-1056.
6. Gravitt PE, Manos MM. 1992. Polymerase chain reaction-based methods for the detection of human papillomavirus DNA. IARC Sci. Publ. 119: 121-133.
7. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. 1998. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J. Clin. Microbiol. 36:3020-3027.
8. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 364:1757-1765.
9. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G. 2006. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 367:1247-1255.
10. Hesselink AT, van Ham MA, Heideman DA, Groothuismink ZM, Rozendaal L, Berkhof J, van Kemenade FJ, Massuger LA, Melchers WJ, Meijer CJ, Snijders PJ. 2008. Comparison of GP5-/6-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J. Clin. Microbiol. 46:3215-3221.
11. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME. 1994. Persistence of type-specific human papillomavirus infection among cytologically normal women. J. Infect. Dis. 169:235-240.
12. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, Lindeman J, ter Harmsel B, Burger M, Quint W. 1999. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 37:2508-2517.
13. Kleter B, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen K, Burger M, ter Harmsel B, Quint W. 1998. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am. J. Pathol. 153:1731-1739.
14. Kreimer AR, Gonzalez P, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Struijk L, Quint W, Chen S, Wacholder S, Hildesheim A, Herrero R. 2011. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: A nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 12:862-870.
15. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G. 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161-2170.
16. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 374:301-314.
17. Perrons C, Jelley R, Kleter B, Quint W, Brink N. 2005. Detection of persistent high risk human papillomavirus infections with hybrid capture II and SPF10/LiPA. J. Clin. Virol. 32:278-285.
18. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. 2011. Human papillomavirus testing in the prevention of cervical cancer. J. Natl. Cancer Inst. 103:368-383.
19. Snijders PJ, van den Brule AJ, Meijer CJ. 2003. The clinical relevance of human papillomavirus testing: Relationship between analytical and clinical sensitivity. J. Pathol. 201:1-6.
20. Thai H, Rangwala S, Gay T, Keating K, McLeod S, Nazarenko I, O'Neil D, Pfister D, Loeffert D. 2009. An HPV 16, 18, and 45 genotyping test based on hybrid capture technology. J. Clin. Virol. 45(Suppl. 1):S93-S97.
21. Tieben LM, ter Schegget J, Minnaar RP, Bouwes Bavinck JN, Berkhout RJ, Vermeer BJ, Jebbink MF, Smits HL. 1993. Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J. Virol. Methods 42:265-279.
22. Tjalma WA, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, Koiss R, O'Leary J, Joura EA, Rosenlund M, Colau B, Schledermann D, Kukk K, Damaskou V, Repanti M, Vladareanu R, Kolomiets L, Savicheva A, Shipitsyna E, Ordi J, Molijn A, Quint W, Raillard A, Rosillon D, De Souza SC, Jenkins D, Holl K. 24 July 2012. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int. J. Cancer 132:854-867.
23. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. 2002. GP5-/6-PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J. Clin. Microbiol. 40:779-787.
24. van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. 2006. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J. Clin. Microbiol. 44:3292-3298.
25. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.
26. Wentzensen N, Vinokurova S, von Knebel DM. 2004. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res. 64:3878-3884.
27. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M. 2012. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by nonvaccine oncogenic HPV types: 4-year endof-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13:100-110.